Please login to the form below

Not currently logged in
Email:
Password:

Tagrisso

This page shows the latest Tagrisso news and features for those working in and with pharma, biotech and healthcare.

AZ’s Sean Bohen to exit after business overhaul; report

AZ’s Sean Bohen to exit after business overhaul; report

to sales growth thanks largely to new cancer drugs Imfinzi, Tagrisso and Lynparza.

Latest news

More from news
Approximately 23 fully matching, plus 28 partially matching documents found.

Latest Intelligence

  • AstraZeneca’s oncology renaissance AstraZeneca’s oncology renaissance

    Eight years on, three new oncology drugs are proving to be the driving force for the new AstraZeneca: small molecule, targeted lung cancer drug Tagrisso (osimertinib) and ovarian cancer treatment Lynparza ... EvaluatePharma forecasts that Lynparza (now co

  • China: AstraZeneca’s new engine for growth and innovation China: AstraZeneca’s new engine for growth and innovation

    In March 2017, AZ’s targeted lung cancer drug Tagrisso was one of the first medicines to gain approval through the Chinese Food and Drug Administration (CFDA)’s Priority Review pathway, ... Liang had been instrumental in building up the company’s

  • Biopharma's Future: Made in China Biopharma's Future: Made in China

    targeted lung cancer drug Tagrisso and diabetes treatment Forxiga.

  • 30 Women Leaders in UK Healthcare 30 Women Leaders in UK Healthcare

    She played a key role in the development and approval of Tagrisso, AstraZeneca’s next-generation EGFR-targeting lung cancer treatment that is proving a major advance on existing treatments, and

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...

Infographics